BJ
NTLA icon

BlackRock Japan’s Intellia Therapeutics NTLA Stock Holding History

BlackRock Japan’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$10K Buy
+776
New +$11.7K ﹤0.01% 1220

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock Japan's NTLA Position: Q4 2016 in Review

BlackRock Japan opened a new position in Intellia Therapeutics (NTLA) in Q4 2016: 776 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #1220 among its holdings.

70 funds tracked by Wall St. Rank hold NTLA as of Q4 2016.

  • BlackRock Japan held 776 shares of Intellia Therapeutics worth $10K as of Q4 2016.
  • Intellia Therapeutics was a new BlackRock Japan position in Q4 2016.
  • Intellia Therapeutics made up ﹤0.01% of BlackRock Japan's portfolio in Q4 2016, its #1220 holding.
  • 70 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2016.

Based on BlackRock Japan's 13F filing for Q4 2016, filed 10 Feb 2017.